143 related articles for article (PubMed ID: 8592995)
1. Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I.
Trafny EA; Stepińska M; Antos M; Grzybowski J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2645-9. PubMed ID: 8592995
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of liposome-encapsulated antibiotics against Pseudomonas aeruginosa attached to the matrix of human dermis.
Trafny EA; Antos-Bielska M; Grzybowski J
J Microencapsul; 1999; 16(4):419-29. PubMed ID: 10420328
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial properties of liposomal polymyxin B.
McAllister SM; Alpar HO; Brown MR
J Antimicrob Chemother; 1999 Feb; 43(2):203-10. PubMed ID: 11252325
[TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
Wilhelm CM; Nunes LS; Martins AF; Barth AL
Diagn Microbiol Infect Dis; 2018 Oct; 92(2):152-154. PubMed ID: 29891185
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro.
Antos M; Trafny EA; Grzybowski J
Pharmacol Res; 1995; 32(1-2):85-7. PubMed ID: 8668652
[TBL] [Abstract][Full Text] [Related]
6. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
Omri A; Suntres ZE; Shek PN
Biochem Pharmacol; 2002 Nov; 64(9):1407-13. PubMed ID: 12392822
[TBL] [Abstract][Full Text] [Related]
7. Anti-pseudomonal activity of collagen sponge with liposomal polymyxin B.
Trafny EA; Grzybowski J; Olszowska-Golec M; Antos M; Struzyna J
Pharmacol Res; 1996 Jan; 33(1):63-5. PubMed ID: 8817648
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
Alipour M; Halwani M; Omri A; Suntres ZE
Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
[TBL] [Abstract][Full Text] [Related]
9. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa.
Omri A; Ravaoarinoro M; Poisson M
J Antimicrob Chemother; 1995 Oct; 36(4):631-9. PubMed ID: 8591937
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa.
Hussein M; Han ML; Zhu Y; Zhou Q; Lin YW; Hancock REW; Hoyer D; Creek DJ; Li J; Velkov T
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611351
[TBL] [Abstract][Full Text] [Related]
11. Adhesion of Pseudomonas aeruginosa to collagen biomaterials: effect of amikacin and ciprofloxacin on the colonization and survival of the adherent organisms.
Trafny EA; Kowalska K; Grzybowski J
J Biomed Mater Res; 1998 Sep; 41(4):593-9. PubMed ID: 9697032
[TBL] [Abstract][Full Text] [Related]
12. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa.
Omri A; Ravaoarinoro M
Chemotherapy; 1996; 42(3):170-6. PubMed ID: 8983883
[TBL] [Abstract][Full Text] [Related]
14. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
15. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Oie S; Sawa A; Kamiya A; Mizuno H
J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987
[TBL] [Abstract][Full Text] [Related]
16. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
Ehsan Z; Clancy JP
Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.
Bratu S; Quale J; Cebular S; Heddurshetti R; Landman D
Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):196-201. PubMed ID: 15772821
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa.
Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL
J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
Yasmin F; Akhtar N; Hameed A
Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
